GlaxoSmithKline Pharmaceuticals Limited (GLAXO) Gross Profit 2022–2026

Name: GlaxoSmithKline Pharmaceuticals Limited (GLAXO) gross profit history 2022-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

GlaxoSmithKline Pharmaceuticals Limited annual gross profit for fiscal 2026 was ₹23.9 billion, an increase of 5.9% from ₹22.5 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

GLAXO Annual Gross Profit

Gross Profit (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Gross Profit	₹23.9B	₹22.5B	₹20.2B	₹18.7B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GLAXO Quarterly Gross Profit

Gross Profit (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31
Gross Profit	₹6.1B	₹6.5B	₹6.8B	₹5.2B	₹6.2B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Gross Profit at Comparable Companies

4568 Gross Profit — Daiichi Sankyo Company, Limited
4503 Gross Profit — Astellas Pharma Inc.
4528 Gross Profit — Ono Pharmaceutical Co., Ltd.
4536 Gross Profit — Santen Pharmaceutical Co., Ltd.
RUBICON Gross Profit — Rubicon Research Limited
NOVN Gross Profit — Novartis AG

More GLAXO metrics: Revenue · Operating Income · Net Income · EPS · Free Cash Flow

All GLAXO financial statements → Interactive GLAXO charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.